Few women utilize tamoxifen to prevent breast cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 2
Volume 19
Issue 2

Less than 1% of women took tamoxifen in the years 2000 and 2005 as a preventive measure, according to results of a recent survey.

Less than 1% of women took tamoxifen in the years 2000 and 2005 as a preventive measure, especially if their personal history of breast cancer was very low, according to results of a recent survey.

Lead investigator Erika A. Waters, PhD, MPH, and colleagues, wanted to evaluate how many women in the U.S., age 40 to 79, took tamoxifen for breast cancer prevention. They mined data from the National Health Interview Surveys for the year 2000 and the year 2005.

The surveys included more than 10,000 women for each year. Dr. Walters is an assistant professor at Washington University School of Medicine in St. Louis, Her co-authors included Andrew N. Freedman, PhD, chief of the clinical and translational epidemiology branch, division of cancer control and population sciences at NCI (Cancer Epidemiol Biomarkers Prev 19:443- 446, 2010).

They found that the prevalence of tamoxifen use in the survey population was very low: 0.2% in 2000 and 0.08% in 2005. The low prevalence of tamoxifen use may stem from various sources, which were not investigated in this study, according to Dr. Freedman.

But "counseling individual women about using tamoxifen to prevent breast cancer must include a patient's discussion with her physician about the drug's risks and benefits, as well as consideration of the patient's personal values, preferences, lifestyle and specific medical situation," he said.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content